Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma Journal Article
| Authors: | Horwitz, S. M.; Feldman, T. A.; Ye, J. C.; Khodadoust, M. S.; Munoz, J.; Hamlin, P. A.; Kim, Y. H.; Wilcox, R. A.; Patel, M. R.; Coffey, G.; Innes, A.; Betz, A.; Holland, J.; Guzman, C. B.; Smith, S. M. |
| Article Title: | Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma |
| Abstract: | In this phase-2a study (NCT01994382), patients aged >= 18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9 months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3 months, respectively. The most common grade >= 3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL. |
| Keywords: | models; peripheral t-cell lymphoma; relapsed/refractory; syk; itk; dual spleen tyrosine kinase/janus kinase inhibitor; phase-2 study |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 66 |
| Issue: | 6 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2025-05-01 |
| Start Page: | 1100 |
| End Page: | 1110 |
| Language: | English |
| ACCESSION: | WOS:001416131000001 |
| DOI: | 10.1080/10428194.2025.2455489 |
| PROVIDER: | wos |
| PUBMED: | 39921522 |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work